Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06943755 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial sites expanded: 126 → 131 locationsEligibility criteria expanded, about 10 wordsShow 1 more changeShow less
Eligibility criteria expanded, about 10 words
MinorStudy sites: 124 to 126v17
MinorTrial sites expanded: 120 → 124 locationsv16
MinorTrial sites expanded: 117 → 120 locationsv15
MinorTrial sites expanded: 97 → 117 locationsv14
MinorTrial sites expanded: 80 → 97 locationsPrimary and study completion dates: Jun 2029 to Jun 30, 2029v13Show 1 more changeShow less
Primary and study completion dates: Jun 2029 to Jun 30, 2029
MinorTrial sites expanded: 66 → 80 locationsv12
MinorStudy sites: 53 to 66v11
MinorStudy sites: 38 to 53v10
MinorStudy sites: 25 to 38v9
MinorStudy sites: 20 to 25v8
MinorStudy sites: 14 to 20v7
MinorStudy sites: 9 to 14v6
MinorStudy sites: 5 to 9v5
MinorStudy sites: 2 to 5Start date changed from estimate of Jul 2025 to Jul 21, 2025v4Show 1 more changeShow less
Start date changed from estimate of Jul 2025 to Jul 21, 2025
MinorStudy sites: 1 to 2v3
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 1v2Show 1 more changeShow less
Study sites: 0 to 1
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.